# STAAR Surgical Company (STAA) fundamentals

Data as of 2026-11-04. NASDAQ, United States. Sector: Healthcare / Medical Instruments & Supplies. Price $25.17, market value $1.3 billion.

## Valuation
- **P/E (trailing): 314.6×** (5-yr avg 98.8×, 3-yr avg 72.6×). STAAR Surgical Company trades at 314.6× trailing earnings, well above its own five-year average of 98.8×: investors are paying up relative to the company's past. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 22.6×, lower than trailing, so analysts expect earnings to grow.
- **Price / sales: 3.7×**. Each dollar of revenue is priced at 3.7×.
- **Price / book: 3.5×**. The shares trade at 3.5× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -0.5%** (5-yr avg -0.6%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.
- **Earnings yield: 0.3%**. The inverse of the P/E: 0.3% of the price is earned each year.

## Profitability
- **Gross margin: 76.6%**. STAAR Surgical Company keeps 76.6% of revenue after the direct cost of what it sells, the kind of margin that comes with software, brands or pricing power.
- **Operating margin: 4.0%**. 4.0% of revenue is left after running the business, which leaves little cushion in a downturn.
- **Net margin: -33.6%**. The company reported a net loss over the last twelve months.
- **Return on equity: -23.4%**. Return on equity is negative because earnings are negative.
- **Return on assets: 0.8%**. Each dollar of assets produces 0.8% of profit.

## Growth
- **Revenue growth (1 yr): -23.7%** (3-yr 0.0%/yr, 5-yr 61.1%/yr). Revenue fell 23.7% over the last year, against 61.1% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): -295.1%**. Earnings per share fell 295.1%, slower than revenue, so margins compressed.

## Financial health
- **Current ratio: 4.55** (quick 4.55). Current assets cover the next year's liabilities 4.55 times.
- **Altman Z-score: 8.62**. A Z-score of 8.62 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 1/9**. 1 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. STAAR Surgical Company does not currently pay a dividend.

## Analyst view
- **Analyst consensus: buy** (9 analysts). 9 analysts cover STAAR Surgical Company; the consensus is buy, with an average price target of $27.67 (+10% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): -3.6%** (YTD 8.0%, 3-mo 2.5%). The shares are down 3.6% over twelve months including dividends.
- **From 52-week high: -29.8%** (61.4% above the low). Trading 30% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 64**. An RSI of 64 is neutral.
- **Beta (1 yr): 0.30** (volatility 55%). Beta of 0.30 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=STAA · Page: https://foliofundamentals.com/stocks/staa

Not investment advice.